Noramco, headquartered in Wilmington, Delaware, is a global leader in the production of controlled substances for the pharmaceutical industry, for medicines used to treat attention deficit hyperactivity disorder, pain, addiction, and for abuse-deterrent formulations. We realize our success through a keen focus on commercial and operational excellence as well as continuing strategic growth. Our global footprint includes Athens, GA, Wilmington, DE and Neuhausen, Switzerland.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

CRESCITA SIGNS EXCLUSIVE 8-COUNTRY LICENSING AGREEMENT WITH EGIS PHARMACEUTICALS FOR PLIAGLIS®

Crescita Therapeutics | December 13, 2021

news image

Crescita Therapeutics Inc. a growth-oriented, innovation-driven Canadian commercial dermatology company, is pleased to announce that it has signed an exclusive commercialization and supply agreement with Egis Pharmaceuticals PLC a leading generic pharmaceutical company in Central Eastern Europe for the rights to Pliaglis in eight countries comprising Hungary, Bulgaria, Czech Republic, Slovakia, Poland, Russia, Latvia and Lithuania. Under the terms of the agreement, Crescita will r...

Read More

CANCER PREVENTION PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR CPP-1X/SUL FOR TREATMENT OF FAMILIAL ADENOMATOUS POLYPOSIS

Cancer Prevention Pharmaceuticals, CPP-1X/sul | June 29, 2020

news image

Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for CPP-1X/sul for treatment of adults with familial adenomatous polyposis (FAP). FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. The clinical...

Read More

PHARMACY MARKET

TARSIER PHARMA RAISES CAPITAL TO EXECUTE PHASE-3 CLINICAL TRIAL

Tarsier Pharma | August 28, 2021

news image

Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced it raised capital to execute a phase-3 clinical trial of its TRS01 program in the US and Europe. Strategic and new investors alongside existing investors participated in this transaction. Following a successful End of Phase II meeting with the FDA, the Company obtained all necessary regu...

Read More

THERMO FISHER SCIENTIFIC LAUNCHES MODULAR CLOSED CELL PROCESSING SYSTEM FOR CELL THERAPY MANUFACTURING

Thermo Fisher | October 15, 2020

news image

Thermo Fisher Scientific announced the launch of its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing. The CTS Rotea system is the first Gibco instrument for cell therapy processing applications and facilitates workflows from research through GMP clinical development and commercial manufacturing. As of mid-2020, 675 clinical trials were underway globally for cell th...

Read More
news image

BUSINESS INSIGHTS

CRESCITA SIGNS EXCLUSIVE 8-COUNTRY LICENSING AGREEMENT WITH EGIS PHARMACEUTICALS FOR PLIAGLIS®

Crescita Therapeutics | December 13, 2021

Crescita Therapeutics Inc. a growth-oriented, innovation-driven Canadian commercial dermatology company, is pleased to announce that it has signed an exclusive commercialization and supply agreement with Egis Pharmaceuticals PLC a leading generic pharmaceutical company in Central Eastern Europe for the rights to Pliaglis in eight countries comprising Hungary, Bulgaria, Czech Republic, Slovakia, Poland, Russia, Latvia and Lithuania. Under the terms of the agreement, Crescita will r...

Read More
news image

CANCER PREVENTION PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR CPP-1X/SUL FOR TREATMENT OF FAMILIAL ADENOMATOUS POLYPOSIS

Cancer Prevention Pharmaceuticals, CPP-1X/sul | June 29, 2020

Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for CPP-1X/sul for treatment of adults with familial adenomatous polyposis (FAP). FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. The clinical...

Read More
news image

PHARMACY MARKET

TARSIER PHARMA RAISES CAPITAL TO EXECUTE PHASE-3 CLINICAL TRIAL

Tarsier Pharma | August 28, 2021

Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced it raised capital to execute a phase-3 clinical trial of its TRS01 program in the US and Europe. Strategic and new investors alongside existing investors participated in this transaction. Following a successful End of Phase II meeting with the FDA, the Company obtained all necessary regu...

Read More
news image

THERMO FISHER SCIENTIFIC LAUNCHES MODULAR CLOSED CELL PROCESSING SYSTEM FOR CELL THERAPY MANUFACTURING

Thermo Fisher | October 15, 2020

Thermo Fisher Scientific announced the launch of its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing. The CTS Rotea system is the first Gibco instrument for cell therapy processing applications and facilitates workflows from research through GMP clinical development and commercial manufacturing. As of mid-2020, 675 clinical trials were underway globally for cell th...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us